|
|
| | Bimagrumab Basic information |
| Product Name: | Bimagrumab | | Synonyms: | Bimagrumab;Research Grade Bimagrumab(DHD72801);Bimagrumab (anti-ACVR2B);Research Grade Bimagrumab | | CAS: | 1356922-05-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Bimagrumab Structure]() |
| | Bimagrumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Bimagrumab Usage And Synthesis |
| Uses | Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness[1][2]. | | in vivo | BYM338 (6-20 mg/kg; s.c. once weekly for 4 weeks) promotes an increase in body weight and skeletal muscle hypertrophy of all examined muscles, slow, fast, and mixed of young SCID mice[2].
BYM338 (5-20 mg/kg; s.c. once weekly for 14 d) prevents Glucocorticoid-induced muscle wasting in mice[2]. | | IC 50 | ACVR2B: 1.7 pM (Kd); ACVR2A: 434 pM (Kd) | | References | [1] Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. DOI:10.1001/jamanetworkopen.2020.33457
[2] Lach-Trifilieff E, et, al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34(4):606-18. DOI:10.1128/MCB.01307-13 |
| | Bimagrumab Preparation Products And Raw materials |
|